Search

Displaying results 4941 - 4950 of 10000 in total
  1. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    [A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. … [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]

  2. Drug

    Lonoctocog alfa

    go.drugbank.com/drugs/DB13998
    ApprovedInvestigational

  3. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    In addition, unlike currently marketed opioids, CR665 does not produce inhibition of intestinal transit (ileus), induce respiratory depression, or elicit signs of euphoria or addiction in animal models … In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.

  4. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

  5. Drug

    MDL72527

    go.drugbank.com/drugs/DB04188
    Experimental

    Categories: Oxidoreductases Acting on CH-NH Group Donors, antagonists & inhibitors
  6. Drug

    Etafenone

    go.drugbank.com/drugs/DB13845
    Experimental

    Etafenone is a vasodilator.

    Categories: Vasodilators Used in Cardiac Diseases
  7. Drug

    Cinepazet

    go.drugbank.com/drugs/DB13342
    Experimental

    Categories: Vasodilators Used in Cardiac Diseases
  8. Drug

    Tirilazad

    go.drugbank.com/drugs/DB13050
    Investigational

    Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  10. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.